Evidence based Evaluation of Antidiabetic Potential of Yesaka on Streptozotocin Diabetic Rats

Yesaka is a known Ayurvedic polyherbal formulation, traditionally employed in the treatment of diabetes mellitus. The current study was performed to evaluate the antidiabetic activity of Yesaka. Antihyperglycemic effects of Yesaka and glipizide were demonstrated in high fat diet-streptozotocin induced diabetic rats. Diabetes was induced by feeding Sprague Dawley rats with high-fat diet (HFD) for two months followed by a single dose of Streptozotocin (STZ, 30mg/kg intraperitoneally). The animals were grouped under normal control and six diabetic subgroups (n=6). All the diabetic rats were orally treated with glipizide as standard (5mg/kg), Yesaka (1.8ml/kg and 3.6ml/kg) and with combination of Yesaka and standard for 4 weeks. The results were assessed by significant restoration of bodyweight, reduction in plasma glucose, total cholesterol (TC), triglycerides (TG), low density lipoprotein-cholesterol (LDL-C) while increased high density lipoprotein cholesterol (HDL-C) levels in all the treatment groups compared to diabetic animals. The antioxidant activity of Yesaka was also evaluated by DPPH. Thus, these findings demonstrated the antidiabetic potential of Yesaka in HFD-fed STZ-treated diabetic rats along with glipizide. Thus, may be a promising candidate in the treatment and management of diabetes with strong antioxidant potential.